Medicare Part D plans and drug makers may apply to participate in a new payment model starting in January, which will allow plan sponsors to offer benefits that limit cost sharing for a 30-day supply of insulin to no more than $35. To encourage participation, the model will give qualifying plans that enroll a high number of insulin-dependent patients the option of additional risk corridor protection for calendar years 2021 and 2022. The model also will test how to encourage healthy behaviors and medication adherence through Part D reward and incentive programs. To participate, drug makers may apply through March 18 and Part D sponsors through May 1. CMS plans to make a list of participating drug makers available to Part D sponsors on or around March 20.

Related News Articles

Headline
Applications for the Rural Health Transformation Program are due Nov. 5 to the Centers for Medicare & Medicaid Services. The program will fund $50 billion…
Headline
The AHA Oct. 3 responded to the Medicare Payment Advisory Commission’s recent analysis on the financial impacts of Medicare Advantage enrollment growth on…
Headline
The federal government shutdown will continue as the Senate Oct. 3 failed to adopt a government funding deal. The latest attempt to pass the House-passed…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 issued a memo, through the Health Plan Management system, finalizing the Medicare Advantage…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The federal government shut down Oct. 1 following a failed Senate vote on the House-passed continuing resolution to fund the government by midnight Sept. 30.…